In breast cancer, this pathway is frequently hyperactivated due to PIK3CA mutations, loss or inactivation of the tumor suppressor PTEN, and hyperactivation of upstream receptor tyrosine kinases (RTKs) such as HER2 and epidermal growth factor receptor (EGFR) [37, 64]. This evidence concerns the gene ERBB2 and breast carcinoma.